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Abstract
Background: Multidrug resistant Acinetobacter baumannii, (MRAB) is an important cause of hospital acquired infection. 
The purpose of this study is to determine the risk factors for MRAB in a city hospital patient population.
Methods: This study is a retrospective review of a city hospital epidemiology data base and includes 247 isolates of 
Acinetobacter baumannii (AB) from 164 patients. Multidrug resistant Acinetobacter baumannii was defined as 
resistance to more than three classes of antibiotics. Using the non-MRAB isolates as the control group, the risk factors 
for the acquisition of MRAB were determined.
Results: Of the 247 AB isolates 72% (177) were multidrug resistant. Fifty-eight percent (143/247) of isolates were highly 
resistant (resistant to imipenem, amikacin, and ampicillin-sulbactam). Of the 37 patients who died with Acinetobacter 
colonization/infection, 32 (86%) patients had the organism recovered from the respiratory tract. The factors which were 
found to be significantly associated (p ≤ 0.05) with multidrug resistance include the recovery of AB from multiple sites, 
mechanical ventilation, previous antibiotic exposure, and the presence of neurologic impairment. Multidrug resistant 
Acinetobacter was associated with significant mortality when compared with sensitive strains (p ≤ 0.01). When surgical 
patients (N = 75) were considered separately, mechanical ventilation and multiple isolates remained the factors 
significantly associated with the development of multidrug resistant Acinetobacter. Among surgical patients 46/75 
(61%) grew a multidrug resistant strain of AB and 37/75 (40%) were resistant to all commonly used antibiotics including 
aminoglycosides, cephalosporins, carbepenems, extended spectrum penicillins, and quinolones. Thirty-five percent of 
the surgical patients had AB cultured from multiple sites and 57% of the Acinetobacter isolates were associated with a 
co-infecting organism, usually a Staphylococcus or Pseudomonas. As in medical patients, the isolation of Acinetobacter 
from multiple sites and the need for mechanical ventilation were significantly associated with the development of 
MRAB.
Conclusions: The factors significantly associated with MRAB in both the general patient population and surgical 
patients were mechanical ventilation and the recovery of Acinetobacter from multiple anatomic sites. Previous 
antibiotic use and neurologic impairment were significant factors in medical patients. Colonization or infection with 
MRAB is associated with increased mortality.
Background
Acinetobacter baumannii, found ubiquitously in the envi-
ronment, is an aerobic gram negative rod which is a non-
fermenter of glucose. When stationary, AB appears as a
coccobacillus, however during growth it takes on a rod
form. Multidrug resistant Acinetobacter baumannii is an
important cause of hospital acquired infection and has
been shown in some studies to increase mortality and
length of stay [1].
Multidrug Resistant Acinetobacter baumannii is often
associated with co-infection by other virulent pathogens.
Thus it is difficult to determine its attributable mortality.
Though MRAB is considered to be a hospital acquired
infection, patients occasionally present with community
acquired colonization of chronic wounds. In order to pro-
vide timely and proper antibiotic therapy it is important
to know the characteristics of those patients with coloni-
zation and invasive infection with MRAB. The purpose of
this study is to determine the resistance patterns of AB in
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a city hospital and to examine the risk factors for coloni-
zation/infection in surgical patients. The source of infec-
tion and the prevalence of co-infecting pathogens will
also be investigated.
Methods
Setting
This research was approved by Institutional Review
Board of Meharry Medical College. The Nashville Gen-
eral Hospital (NGH) is a 200 bed teaching tertiary safety
net hospital which serves a population of 1.5 million peo-
ple. NGH also serves as a major provider of inpatient care
for the Tennessee Department of Corrections. The medi-
cal/surgical intensive care unit has 18 beds and is a com-
bined general medical and surgical semi-closed unit.
Study design
This study is a retrospective review of a city hospital epi-
demiology data base and includes 247 isolates of AB from
164 patients. For the period 2006 through 2008 a retro-
spective chart review was performed on all patients with
AB isolates. The patients were identified through the hos-
pital infection control data base. Documented patient
demographics and potential risk factors included diagno-
sis, length of stay, patient location, age, sex, race, previous
institutionalization, previous antibiotic use, mechanical
ventilation, tracheostomy, and underlying co-morbidity.
The source of the AB isolates was also noted as well as the
patient outcome.
Previous institutionalization included prior hospitaliza-
tion, nursing home residency, or incarceration within 90
days of a positive AB culture date. Prior antibiotic use was
noted for those patients who received an antibiotic within
one month of the AB isolation. The resistance patterns of
all isolates were included in the analysis; however
patients with more than one isolate were counted only
once. The source of the AB isolate is the anatomic site
where the culture was obtained.
Identification and characterization of MRAB
The identification of the isolates as Acinetobacter and
susceptibility testing of those isolates was performed
using a Siemens (formerly Dade Behering) microscan sys-
tem, which is FDA approved for this use in clinical labo-
ratories. Testing was performed according to
manufacturer specifications for this instrument and was
done in accordance with NCCLS recommended prac-
tices. This instrument makes use of broth microdilution
methodology to determine resistance. An isolate was
deemed pan-sensitive if it was sensitive to all commonly
tested antibiotics except colistin and highly sensitive if it
was sensitive to imipenem, amikacin, and ampicillin-sul-
bactam. The isolate was considered highly resistant if it
was resistant to imipenem, amikacin, and ampicillin-sul-
bactam. An isolate was classified as pan-resistant if it was
resistant to all commonly used antibiotics. Multidrug
resistant Acinetobacter baumannii isolates are defined as
those resistant to more than three classes of antibiotics. A
distinction was made between carbepenems and the non-
carbepenem β-lactam antibiotics because carbapenem
resistance is a sentinel event for emerging antimicrobial
resistance and in itself confers high resistance. This study
is designed to document the risk factors for the isolation
of MRAB in our surgical patient population, thus no
attempt was made to distinguish between colonization
and invasive infection. The differences between groups
were determined by Student's T-test for continuous data
or the Fisher's exact test for categorical data (2-tailed).
The significance level threshold was a p-value of ≤ 0.05.
Results
Multidrug resistant Acinetobacter baumannii is defined
as resistance to more than three classes of antibiotics. Of
the 247 AB isolates, 177 (72%) were multidrug resistant.
More than half of the isolates, 143/247 (58%) were resis-
tant to imipenem, amikacin, and ampicillin-sulbactam;
thus classifying these isolates as highly resistant. This is
intriguing as these antibiotics were formerly very effec-
tive against AB. Only 42 (17%) of the isolates were sensi-
tive to all three of the above antimicrobial agents. Forty-
six percent (113/247) of the isolates were resistant to all
commonly used antibiotics including aminoglycosides,
cephalosporins, carbepenems, extended spectrum peni-
cillins, and quinolones and therefore were classified as
pan-resistant.
The sources of AB isolates in all patients are shown in
Table 1. The major site of AB isolation in this study was
the respiratory tract. Due to the inconsistency of obtain-
ing quantitative cultures it was not possible to determine
infection vs. colonization, however 32/37 (86%) of all
patients who died had a positive isolate recovered from
the respiratory tract. Among the positive wound isolates
the majority were from chronic diabetic wounds, ampu-
tation sites, and decubitus ulcers. Using the non-MRAB
isolates as the control group, the risk factors for the
acquisition of MRAB were determined (Table 2). The fac-
tors which were significantly associated with multidrug
resistance include the recovery of Acinetobacter from
multiple sites, mechanical ventilation, previous antibiotic
use, and the presence of co-morbidity (especially neuro-
logic impairment). Diabetes mellitus and the previous use
of quinolones trended toward significance.
Forty six percent of the total patients (75/164) were
admitted to the surgical service and the analysis appears
in Table 3. The sites of AB isolation in surgical patients
were wounds 36 (47.4%), respiratory tract 17 (23%), uri-
nary tract 14 (18%), blood 5 (7%) and vascular catheters 3
(4%). Thirty-five percent of the surgical patients had ABDent et al. BMC Infectious Diseases 2010, 10:196
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cultured from multiple sites and 57% percent of the AB
isolates in surgical patients were associated with a co-
infecting organism, usually a Staphylococcus or
Pseudomonas (Table 4). While the finding of Acineto-
bacter in multiple sites was associated with increased
likelihood of multidrug resistance (p ≤ 0.01), no signifi-
cant association was found for co-infecting organisms.
Among surgical patients 46/75 (61%) of isolates were
MRAB and 37/75 (40%) were resistant to all commonly
used antibiotics. The majority of surgical patients with
positive AB isolates (69%) had been institutionalized as
inpatients, nursing home residents, or inmates within 90
days prior to the positive AB culture. Peculiar to this hos-
pital population, 18 (24%) of surgical patients had been
incarcerated. Three patients (4%) had Acinetobacter
recovered from chronic wounds without a history of
prior institutionalization. Twenty six surgical patients
(35%) required mechanical ventilation or tracheostomy.
Mechanical ventilation (p < 0.01) was significantly associ-
ated with the development of MRAB.
The majority (92%) of surgical patients with AB coloni-
zation received antibiotics within 30 days of the positive
culture. The most frequent antibiotics prescribed were
non-carbepenem β-Lactams (39%), and flouroquinolones
(27%), aminoglycosides (15%), and carbepenems (13%).
Overall prior exposure to antibiotics was not a significant
risk factor in the development of MRAB in this group of
surgical patients, however the previous use of non-car-
bepenem β-lactams trended toward significance (p =
0.07).
A co-morbidity was present in 63(84%) of surgical
patients but overall was not a risk factor for MRAB in this
study (p = 0.32). The most frequent co-morbidity associ-
ated with MRAB in this study is diabetes mellitus 27/75
(36%), followed by chronic obstructive pulmonary disease
(12%), neurological impairment (9%), and cardiovascular
disease (8%).
With regard to outcome, 41% of patients were dis-
charged to home, 32% were discharged to nursing homes
or transferred to other inpatient facilities, and 16% died.
The mean length of stay for sensitive and multidrug resis-
tant Acinetobacter (32 vs. 29 days) was not significantly
different (p>0.05). Of the surgical deaths, all patients had
MRAB and 9/12(75%) were colonized or infected with
pan-resistant AB. Overall, the presence of co-infection
with other organisms did not contribute significantly to
mortality (p = 0.75). The only organism that approached
significance with respect to affecting survival was
Pseudomonas aeruginosa (p = 0.07).
Discussion
Acinetobacter baumannii has become an important
pathogen in recent years and has been shown to increase
morbidity and mortality [1-3]. The definition of MRAB
varies in the literature, but several authorities consider an
isolate to be multidrug resistant if it is resistant to three
or more classes of antibiotics [4]. Resistant AB is a signifi-
cant problem as seen in this study where 72% of isolates
were considered multidrug resistant and 58% were resis-
tant to imipenem, amikacin, and ampicillin-sulbactam,
formerly very effective antibiotics. Nearly half (46%) of all
isolates were resistant to all commonly used antibiotics
including aminoglycosides, cephalosporins, carbepen-
ems, extended spectrum penicillins, and quinolones. A
distinction was made between carbepenems and the non-
carbepenem β-lactam antibiotics because carbapenem
resistance is a sentinel event for emerging antimicrobial
resistance and in itself confers high resistance and thera-
peutic challenges [5].
The factors associated with the isolation of AB in our
combined medical and surgical patient groups include
mechanical ventilation, previous antibiotic therapy, co-
morbidity, especially neurologic impairment, and multi-
ple Acinetobacter isolates. The significant factors for
MRAB in the surgical group were mechanical ventilation,
multiple isolates, and neurologic impairment. These find-
ings are consistent with other reports [6-9]. The most fre-
quent antibiotics prescribed in this study population were
β-lactams, followed by flouroquinolones, aminoglyco-
sides, and carbepenems. The prior exposure to quinolo-
nes trended toward significance which is documented in
previous reports [10].
Several investigators have found an association of
MRAB with co-morbidities [7]. Our patients had signifi-
cant rates of diabetes mellitus, cardiovascular disease,
chronic obstructive lung disease and neurological impair-
ment. A co-morbid condition was found in 84% of our
surgical cohort, however only neurologic impairment
Table 1: Sources of 247 multi-resistant Acinetobacter 
baumannii isolates
N%
Sputum 77 31
Urine 40 16
Extremity Wounds 32 13
Other 30 12
Blood 26 10
CVP Catheter 23 9
Decubitus Ulcer 19 8Dent et al. BMC Infectious Diseases 2010, 10:196
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achieved significance. Neurologic injury, in particular
paraplegia has been shown to be associated with the
development of resistant Acinetobacter [11]. Our neuro-
logically impaired population had a high prevalence of
chronic wounds such as decubitus ulcers and most were
nursing home residents. This most likely explains the sig-
nificant increased risk of resistant Acinetobacter in this
group.
Chronic obstructive pulmonary disease and diabetes
showed a trend toward significant associations with the
development of multidrug resistant Acinetobacter. It is
well accepted that patients with chronic lung disease are
at increased risk of airway colonization and pneumonia,
especially when they require intubation [12]. Addition-
ally, intubated patients with chronic pulmonary disease
are often treated with prophylactic antibiotics which
increase the risk of resistance. The association with dia-
betes is most likely related to the high prevalence of
chronic diabetic lower extremity wounds in this patient
population.
As in several other studies, this descriptive study attests
to the ability of AB to colonize/infect soft tissue and bone
[13,14]. Nearly half (47%) of our surgical patients had
resistant AB in chronic diabetic wounds, amputation
sites, or decubitus ulcers. Several our patients had multi-
ple positive cultures of their wounds over a period of sev-
eral months. These patients are chronic carriers of
resistant AB who may develop life threatening invasive
infection or serve as portals of entry of resistant AB into
the hospital. Whether routine surveillance and isolation
Table 2: Risk factors for 247 isolates of multi-resistant Acinetobacter baumannii (all patients, N = 164)
Risk factor MDRAB Control p-value1 Odds 95% C.I2
(N = 122) (N = 42) Ratio
Surgical admission 53 22 0.32 0.70 0.35-1.141
Age > 55 49 12 0.18 1.68 0.78 - 3.59
Male Gender 90 27 0.24 1.56 0.74 - 3.30
Institutionalized < 90 days prior to admission 91 32 0.84 0.92 0.41 - 2.08
Multiple Isolates 53 3 < 0.01 9.98 2.93-34.08
Mechanical Ventilation 65 3 < 0.01 14.82 4.35 - 50.57
Previous antibiotics 111 33 0.03 2.75 1.05 - 7.21
Quinolone 50 11 0.09 1.96 0.90 - 4.26
Co-morbidity3 111 33 0.03 2.75 1.05-7.21
COPD4 19 2 0.07 3.69 0.82 - 16.57
Neurologic impairment5 27 3 0.03 3.69 1.06 - 12.89
Diabetes mellitus 35 19 0.05 0.49 0.24 - 1.00
Mortality 36 1 < 0.01 17.24 1.70 - 83.33
1 p-values derived from Fisher's exact test
2 C.I. - 95% Confidence Interval
3 Congestive heart failure, chronic pancreatitis, peripheral vascular disease, coronary artery disease, chronic obstructive pulmonary disease, 
diabetes mellitus, end stage renal disease, asthma, cancer, obesity, hepatitis, human immunodeficiency virus
4COPD - Chronic Obstructive Pulmonary Disease
5Cerebrovascular accident, Traumatic brain injury, Alzheimer's disease, Spinal cord injuryDent et al. BMC Infectious Diseases 2010, 10:196
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of these patients may help to prevent outbreaks is unclear
[11].
Previous institutionalization (hospital, prison, or nurs-
ing home) did not reach the level of significance (p =
0.07) as a factor in the development of MRAB in this
study. The reason for this finding is unclear since several
s t u d i e s  h a v e  d o c u m e n t e d  h i g h e r  r a t e s  o f  M R A B  i n
patients with a history of prior institutionalization [8].
Our patient population is unusual due to the large num-
ber (24%) of incarcerated individuals. Three patients (4%)
had multidrug resistant Acinetobacter despite having no
history of being institutionalized. The existence of com-
munity acquired MRAB strains would present significant
challenges to infection control.
As seen in Tables 1 and 2, MRAB was associated with a
significant (p < 0.01) increase in mortality. An increase in
mortality for ventilator associated Acinetobacter pneu-
monia has been noted in several studies [2,15,16], how-
ever other investigators have not confirmed this finding
[17,18]. In the surgical group, a significant proportion
(35%) had positive Acinetobacter cultures from multiple
sites. Multiple isolates were associated with a significant
increase in mortality. The finding of resistant AB isolates
in more than one anatomic site most likely signifies an
invasive infection rather than colonization. The majority
of surgical patients (57%) had an organism other than AB
identified on culture, usually a Staphylococcus or
Pseudomonas. Co-infection with non-Acinetobacter
organisms did not lead to a significant increase in mortal-
ity. Pseudomonas was the only organism that approached
significance with respect to mortality (p = 0.07)
There was no significant difference in the length of stay
between patients with sensitive isolates vs. multidrug
resistant Acinetobacter. This finding was somewhat sur-
prising given that some studies have shown an increase
length of stay for resistant strains. The length of stay in
patients with resistant organisms may be confounded by
their increased mortality. The mortality rate in surgical
patients was 16% and all had resistant Acinetobacter.
Most of the surgical patients who died (75%) grew pan-
resistant strains which were resistant to all commonly
used antibiotics. Underlying co-morbidities and co-
infecting organisms did not significantly impact mortality
in this study, whereas the presence of a multidrug resis-
tant Acinetobacter was associated with increased mortal-
ity (OR 1.6, 95% C.I 1.33-1.96). This suggests that
colonization/infection with MRAB is a marker for severe
illness or that the organism itself is responsible for poor
outcome.
This study is limited because it does not identify
patients with true infections versus those that are colo-
nized. The goal was to determine the impact of MRAB in
Table 3: Risk Factors for multi-resistant Acinetobacter baumannii in surgical patients (N = 75)
Risk factor MDRAB1 Control p-value2 Odds 95% C.I.3
(N = 51) (N = 24) Ratio
Age > 55 19 9 0.37 1.56 0.59-4.17
Male Gender 33 19 0.57 1.34 0.49 - 3.63
Institutionalized < 90 days prior to admission 32 20 0.96 1.03 0.38 - 2.82
Multiple Isolates 22 5 < 0.01 4.40 1.43 - 13.54
Mechanical Ventilation 22 4 < 0.01 5.73 1.72 - 19.09
Previous Antibiotics 41 25 0.73 1.31 0.32 - 5.35
Co-infection 26 8 0.64 1.09 0.76 - 1.56
Co-morbidity 41 23 0.32 2.14 0.59 - 7.79
Mortality 12 0 0.01 1.85 1.48 - 2.33
1Multi-resistant Acinetobacter baumannii
2 p-values derived from Fisher's exact test
3C.I. - 95% Confidence intervalDent et al. BMC Infectious Diseases 2010, 10:196
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our hospital. The mortality rate in this study of 16% is
consistent with a similar study reported by Mahgoub [9].
Of note is that the rate of MRAB in our hospital was 122/
164 (75%) which is higher than reported elsewhere [19].
The cause of the high rate of multi-resistance is not
known and our study design does not enable us to answer
this question. We are not certain what role our infection
control procedures had on the high resistance rate. Stan-
dard infection control practices were followed (hand
hygiene, personal protective equipment, environmental
control, isolation, etc). Most of the resistant cases (75%)
occurred in the ICU, however antibiotic susceptibilities
and the anatomical sources varied greatly. We speculate
that since different strains were involved, it is unlikely
that a breakdown in infection control was the major
cause of the high rate of resistance. Initially, the multi-
resistant isolates were confirmed by an independent labo-
ratory. Thus, we are confident concerning our determina-
tion of the antibiotic susceptibilities. We are planning a
future study to determine the DNA fingerprinting of sev-
eral of the more common resistant phenotypes in our
hospital.
Conclusions
The factors associated with multidrug resistant isolates in
this study were mechanical ventilation, previous antibi-
otic use, neurologic impairment, and the recovery of
Acinetobacter from more than one anatomic site. This
study also suggests that infection or colonization with
MRAB is associated with increased mortality. The
increasing presence of MRAB in wounds is particularly
problematic in the surgical patient. Chronic wounds such
as amputation stumps, decubitus ulcers, and diabetic
wounds are portals of entry of Acinetobacter into the sur-
gical intensive care unit. A small number of patients pres-
ent with community acquired multidrug resistant strains,
thus routine surveillance may be useful to guide hospital
infection control measures. Vigilance is needed by the
surgical team to prevent outbreaks of this opportunistic
and deadly pathogen.
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